The development of a thirst provocation test using the AVP receptor antagonist Tolvaptan for quantification of thirst sensation in various patient groups (obese patients with and without a history of bariatric surgery, patients with congestive heart failure and patients with cranial diabetes insipidus as compared to healthy controls) and genotyping of the AVP receptor 2.

Withdrawn

Conditions: abnormal thirst
pathological thirst sensation
10019280
10021112
10017998

Registration Number: NL-OMON38159

Lead Sponsor: Reinier de Graaf Groep

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Withdrawn

Sex: Not specified

Target Recruitment: 60

Inclusion Criteria

1. Informed consent signed by all healthy probands and patients
2. Male and female probands and patients, age 18 - 65 years
3. For obese patients with a history of Bariatric Surgery: Pre-BS BMI >27 Kg/m2
4. For obese patients without a history of BS: BMI >27 Kg/m2
5. For obese patients with a history of BS: operation at least 2 years ago, stable weight for at least a year

Exclusion Criteria

1. Unwillingness to cooperate with the study procedures
2. History of an active malignancy
3. No written informed consent
4. Pregnancy
5. Breastfeeding
6. Urinary tract obstruction like benign prostate hyperplasia, or patients otherwise unable to void
7. (A history of) electrolyte disturbances or renal failure
8. Diabetes mellitus (as this can cause pseudohyponatraemia)
9. Lactose- or galactose intolerance
10. Clinical signs of dehydration
11. Failure to meet the inclusion criteria

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main objective of this study is to determine the effects of BS, heart<br /><br>failure and diabetes insipidus on thirst sensation as measured on a visual<br /><br>analogue scale (VAS).</p><br>

Secondary Outcome Measures